MoonLake ImmunotherapeuticsMEX:MLTXN 30 Market Cap is MXN29,477.41 Mil as of Jun. 26, 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,431 Biotechnology companies, MoonLake Immunotherapeutics ranks better than 85.67% on this metric.
MoonLake Immunotherapeutics's quarterly market cap
increased
from Sep. 2025 (MXN68,431.91 Mil) to Dec. 2025 (MXN76,669.95 Mil) but then
declined
from Dec. 2025 (MXN76,669.95 Mil) to Mar. 2026 (MXN22,022.51 Mil).
MoonLake Immunotherapeutics's annual market cap
increased
from Dec. 2023 (MXN45,349.50 Mil) to Dec. 2024 (MXN67,757.31 Mil) and
increased
from Dec. 2024 (MXN67,757.31 Mil) to Dec. 2025 (MXN76,669.95 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MoonLake Immunotherapeutics's Enterprise Value for Today is MXN24,944.60 Mil.
MoonLake Immunotherapeutics (MEX:MLTXN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
MoonLake Immunotherapeutics Market Cap Related Terms
MoonLake Immunotherapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MLTXN vs AVBP, BCAX, KALV: Market Cap Comparison
For the Biotechnology subindustry, MoonLake Immunotherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MoonLake Immunotherapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where MoonLake Immunotherapeutics's Market Cap falls into.
MoonLake Immunotherapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MoonLake Immunotherapeutics (MEX:MLTXN) has a Market Cap of MXN29,477.41 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MoonLake Immunotherapeutics and its competitors. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #205 out of 1431 companies in the Biotechnology industry, placing it in the top 14.3%.
Is MoonLake Immunotherapeutics' Market Cap too high?
MoonLake Immunotherapeutics' current Market Cap is MXN29,477.41 Mil. Based on the distribution chart, MoonLake Immunotherapeutics ranks #205 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Market Cap compare to AVBP and BCAX?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #205 out of 1431 companies for Market Cap. This places MoonLake Immunotherapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MoonLake Immunotherapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current Market Cap is MXN29,477.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current Market Cap of MXN29,477.41 Mil. The current Market Cap is MXN29,477.41 Mil. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current Market Cap is MXN29,477.41 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score
Get the complete analysis for MEX:MLTXN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MLTXN has been successfully added to your 
